

Date: 17.11.2021

To,

Securities and Exchange Board of India
Plot No. C4-A, 'G' Block,
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Dear Sir/ Madam,

Sub: Disclosure under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

I, S. Nagi Reddy, promoter of M/s Concord Drugs Limited has acquired 3,97,500 equity Shares through inter-se transfer. In this regard, I enclose herewith the following documents:

- 1) Disclosure Form under Regulation 10(7) made in reliance upon exemption provided for in regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
- 2) Processing charges of Rs.1,50,000 has been paid on 16.11.2021 through NEFT bearing UTR No SBIN121320363743.

This is for kind information and records of SEBI, please.

Thanking you.

Yours faithfully,

S. Nagi Reddy

S. Nagi Reddy

Encl: as above

- 1.) Report filed with Stock exchanges u/r 10(5)
- 2.) Report filed with Stock exchanges u/r 10(6)
- 3.) Disclosures u/r 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
- 4.) Disclosures u/r 13 of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Format under Regulation 10(7) – Report to SEBI in respect of any acquisition made in reliance up on exemption provided for in regulation 10(1)(a)(i) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011

1	General Details	
a.	Name, address, telephone no., e-mail of acquirer(s) {In case there are multiple acquirers, provide full contact details of any one acquirer (the correspondent acquirer) with whom SEBI shall correspond.}	S. Nagi Reddy House No. 3-11-1/1 L.B. Nagar, Hyderabad – 500074, Telangana Contact No: 9849016762 Email: nagireddy1969@gmail.com
b.	Whether sender is the acquirer (Y/N)	Y
c.	If not, whether the sender is duly authorized by the acquirer to act on his behalf in this regard (enclose copy of such authorization)	N.A.
d.	Name, address, Tel no: and e-mail of the sender, if sender is not the acquirer	N.A.
2	Compliance of Regulation 10(7)	
a.	Date of report	17.11.2021
b.	Whether report has been submitted to SEBI within 21 working days from the date of the acquisition	Yes
c.	Whether the report is accompanied with fees as required under Regulation 10(7)	Yes
3	Compliance of Regulation 10(5)	
a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed, at least 4 working days before the date of the proposed acquisition	Yes
b.	Date of Report	05.11.2021
4	Compliance of Regulation 10(6)	
a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed within 4 working days after the date of the proposed acquisition	Yes
b.	Date of Report	15.11.2021
5	Details of the Target Company (TC)	
a.	Name & address of TC	Concord Drugs Limited Survey No.249, Brahmanapally Village Hayatnagar Mandal R.R.Dist- 501511 Telangana

	b.	Name of the Stock Exchange(s) where the shares of the TC are listed	BSE Limited			
6	Details of the acquisition					
	a.	Date of acquisition	15.11.2021			
	b.	Acquisition price per share (in Rs.)	Not Applicable as it is a gift transaction			
	c.	Regulation which would have been triggered an open offer, had the report not been filed under Regulation 10(7). (whether Regulation 3(1), 3(2), 4 or 5)	3(1) and 3(2)			
	d.	Shareholding of acquirer/s and PACs individually in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)(*)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital of TC	No. of Shares	% w.r.t total share capital of TC
			Name of the acquirer/s / PACs			
			18,86,899	21.58	22,84,399	26.13
			10,00,000	11.44	10,00,000	11.44
		10,00,000	11.44	10,00,000	11.44	
	e.	Shareholding of seller/s in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital of TC	No. of Shares	% w.r.t total share capital of TC
			Name of the seller Vundela Ramasubba Reddy			
		3,97,500	4.55	-	-	
7	Information specific to the exemption category to which the instant acquisition belongs Regulation 10(1)(a)(i)					
	a.	Provide the names of the seller/s	Vundela Ramasubba Reddy			
	b.	Specify the relationship between the acquirer/s and the seller/s.	Both acquirer and seller are immediate relatives. Also they are named as promoters in the shareholding pattern filed by the target company for not less than three years prior to the proposed acquisition			

c.	Confirm whether the acquirer(s) and the seller(s) are immediate relatives as defined in the regulation 2(l)	Yes
d.	If shares of the TC are frequently traded, volume-weighted average market price (VWAP) for a period of sixty trading days preceding the date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	Rs. 29.28. However, it is a gift transaction.
e.	If the shares of the TC are infrequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not Applicable

I/We hereby declare that the information provided in the instant report is true and nothing has been concealed there from.

Signature: *S. N. Reddy*

Place: Hyderabad

Date: 17.11.2021

NOTE:

- (*) In case, percentage of shareholding to the total capital is different from percentage of voting rights, indicate percentage of shareholding and voting rights separately. *The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI (Substantial Acquisition of Shares and Takeover Regulations) 2011*

To,

Date: 15.11.2021

BSE Limited
P.J. Towers, Dalal Street
Dear Sir/ Madam,

Sub: Disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


Ref: My letter dated 05.11.2021

I, S. Nagi Reddy, promoter of M/s Concord Drugs Limited have acquired 3,97,500 equity shares through inter se transfer. In this regard, I enclose herewith disclosure in prescribed Form under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

This is for your information and records, please.

Thanking you.

Yours faithfully,


S. Nagi Reddy

Encl: As above.

Format for Disclosures under Regulation 10(6) – Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Concord Drugs Limited Survey No.249, Brahmanapally Village Hayatnagar Mandal R.R.Dist- 501511 Telangana		
2.	Name of the acquirer(s)	S. Nagi Reddy		
3.	Name of the stock exchange where shares of the TC are listed	BSE Limited		
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	Inter-se transfer between promoters who are immediate relatives		
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Reg.10(1)(a)(i)		
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Yes, disclosure of proposed acquisition was required to be made under regulation 10 (5) Yes, disclosure was made within the timeline specified under the regulations. 05.11.2021		
7.	Details of acquisition	Disclosures made/required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made	
	a. Name of the transferor / seller	Vundela Ramasubba Reddy	Yes	
	b. Date of acquisition	15.11.2021	Yes	
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	3,97,500 Equity shares	Yes	
	d. Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	3,97,500 Equity shares (4.55%)	Yes	
	e. Price at which shares are proposed to be acquired / actually acquired	N.A. as it is a gift transaction	Yes	
8.	Shareholding details	Pre-Transaction		Post-Transaction
		No. of shares held	% w.r.t total share capital of TC	No. of shares held % w.r.t total share capital of TC

	Each Acquirer / Transferee(*) S. Nagi Reddy	18,86,899	21.58	22,84,399	26.13
	Each Seller / Transferor Vundela Ramasubba Reddy	3,97,500	4.55	-	-

Place: Hyderabad
Date: 15.11.2021

S. Nagi Reddy
S. Nagi Reddy

Note:

- (*) Shareholding of each entity shall be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

To,

Date: 05.11.2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Dear Sir/ Madam,

Sub: Disclosure under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


I, S. Nagi Reddy, promoter of M/s Concord Drugs Limited propose to acquire 3,97,500 equity Shares constituting 4.55% of the paid up capital of the company from Vundela Ramasubba Reddy, another promoter of the Company through inter se transfer. In this regard, I enclose herewith disclosure in prescribed Form under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

During the financial year, as on date, the promoters have acquired 4,04,359 equity shares constituting 4.63% and as a result the promoters equity have gone up from 44.38% as on 31.03.2021 to 49.01% as on date. With the proposed inter-se transaction, the promoters will exceed acquisition of shares by more than 5% in a financial year.

This is for your information and records, please.

Thanking you.

Yours faithfully,



S. Nagi Reddy

Encl:

- 1) Declaration by Mr. S. Nagi Reddy that both the transferor and the transferee will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 as **Annex - 1**.
- 2) Declaration by Mr. S. Nagi Reddy that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with as **Annex - 2**.

Format for Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respect of acquisition under regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Concord Drugs Limited Survey No.249, Brahmanapally Village Hayatnagar Mandal R.R.Dist- 501511 Telangana
2.	Name of the acquirer(s)	S. Nagi Reddy
3.	Whether the acquirer(s) is/are promoter(s) of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters	Yes
4.	Details of proposed acquisition	
	a.	Name of the person(s) from whom shares are to be acquired
	b.	Proposed date of acquisition
	c.	No. of shares to be acquired from each person mention in 4(a) above
	d.	Total shares to be acquired as percentage of share capital of the TC
	e.	Price at which shares are proposed to be acquired
	f.	Rationale, if any for the proposed transfer
5.	Relevant sub clause of Regulation 10(1)(a) under which the acquirer is exempted from making open offer	10(1)(a)(i)
6.	If frequently traded, volume-weighted average market price (VWAP) for a period of sixty trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period	Rs.29.28 per share. However it is not applicable as the proposed transaction does not involve any consideration amount.
7.	If infrequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	The shares are frequently traded.
8.	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable	Not applicable as the proposed transaction does not involve any consideration amount.
9.	Declaration by the acquirer, that the transferor and transferee have complied/ will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)	Attached as Annexure 1
10	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	Attached as Annexure 2

S, Nagi Reddy

11	Shareholding details	Before the proposed transaction		After the proposed transaction	
		No. of shares Voting rights	% w.r.t total share capital of TC	No. of shares voting rights	% w.r.t total share capital of TC
a	Acquirer (s) and PACs (other than sellers)(*)				
	S. Nagi Reddy	18,86,899	21.58	22,84,399	26.13
	S. Koni Reddy	10,00,000	11.44	10,00,000	11.44
	S. Manoj Reddy	10,00,000	11.44	10,00,000	11.44
b	Seller(s)				
	Vundela Ramasubba Reddy	397,500	4.55	-	-

Place: Hyderabad
Date: 05.11.2021

S. Nagi Reddy
S. Nagi Reddy

Note:

(*) Shareholding of each entity shall be shown separately and then collectively in a group.

- The above disclosure shall be signed by the promoter mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorised to do so.

Annexure 1

DECLARATION

I, S. Nagi Reddy acquirer of 3,97,500 equity shares of M/s. Concord Drugs Limited hereby declare that the transferor, Vundela Ramasubba Reddy and transferee, i.e. myself will comply with applicable disclosure requirements in Chapter V of the SEBI Takeover Regulations, 2011.

Place: Hyderabad
Date: 05.11.2021


S. Nagi Reddy
S. Nagi Reddy
Acquirer

Annexure 2

DECLARATION

I, S. Nagi Reddy acquirer of 3,97,500 equity shares of M/s. Concord Drugs Limited hereby declare that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.

Place: Hyderabad
Date: 05.11.2021


S. Nagi Reddy
Acquirer

To,

Date: 15.11.2021

1. BSE Limited P.J. Towers, Dalal Street, Mumbai – 400001	2. Concord Drugs Limited Survey No.249, Brahmanpally Village, Hayatnagar Mandal, R.R. Dist, Hyderabad, Telangana, 501511
---	---

Dear Sir/ Madam,

Sub: Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Unit: Concord Drugs Limited

I, S. Nagi Reddy, Promoter of the company have acquired 3,97,500 Equity Shares through inter-se transfer. In this regard, I enclose herewith prescribed Form C under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Sincerely,

S. Nagi Reddy
S. Nagi Reddy

Encl: As above

FORM C

**SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7(2) read with Regulation 6(2) Continual disclosure]**

Name of the company: CONCORD DRUGS LIMITED

ISIN of the company: INE858L01010

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoters Member of Promoter Group/ Designated Person/ Director/ Immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/Disposed			
		Type of security (For e.g. – Shares, Warrants, Convertible Debentures, Rights Entitlements etc.)	No. and % of shareholding	Type of securities (For e.g.– Shares, Warrants, Convertible Debentures, Rights Entitlements etc.)	No.	Value	Transaction Type (Purchase/ Sale/Pledge/ Revocation/ Invocation/ Others-please specify)
1	2	3	4	5	6	7	8
Name: S. Nagi Reddy PAN: AIRPS8676D Address: House No. 3-11-1/1 L.B. Nagar, Hyderabad – 500074, Telangana Mobile No. 9849016762	Promoter and Managing Director	Equity Shares	18,86,899 (21.58%)	Equity Shares	3,97,500	NA (Gift)	Others - Interse-transfer

Securities held post acquisition/disposal		Date of allotment advice/ acquisition of shares/disposal of shares specify		Date of intimation to company	Mode of acquisition /disposal (on market/public/ rights/preferential offer/off market/Inter-se transfer, ESOPs etc.)	Exchange on which the trade was executed
Type of securities (For e.g.- Shares, Warrants, Convertible Debentures, Rights Entitlements etc.)	No. and % of shareholding	From	To			
9	10	11	12	13	14	15
Equity Shares	22,84,399 (26.13%)	15.11.2021	15.11.2021	15.11.2021	Inter-se transfer	NA

Note: (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

(ii.) Value of transaction excludes taxes/brokerage/any other charges

Details of trading in derivatives of the company by Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Type of contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
16	17	18	19	20	21	22
Nil	Nil	Nil	Nil	Nil	Nil	Nil

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

S. Nagi Reddy
(S. Nagi Reddy)

Promoter

Date: 15.11.2021
Place: Hyderabad

To,

Date: 15.11.2021

1. BSE Limited P.J. Towers, Dalal Street, Mumbai – 400001	2. Concord Drugs Limited Survey No.249, Brahmanpally Village, Hayatnagar Mandal, R.R. Dist, Hyderabad, Telangana, 501511
---	---

Dear Sir/ Madam,

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


Unit: **Concord Drugs Limited**

I, S. Nagi Reddy, Promoter of the company have acquired 3,97,500 Equity Shares through inter se transfer. In this regard, I enclose herewith prescribed Form 29(2) under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Sincerely,


S. Nagi Reddy

Encl: As above.


Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	CONCORD DRUGS LIMITED		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	S. Nagi Reddy		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights	18,86,899	21.58	21.58
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)	-	-	-
c) Voting rights (VR) otherwise than byshares	-	-	-
d) Warrants/convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	18,86,899	21.58	21.58
Details of acquisition			
a) Shares carrying voting rights acquired	3,97,500	4.55	4.55
b) VRs acquired /sold otherwise than byshares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
d) Shares encumbered / invoked/released by theacquirer	-	-	-
e) Total (a+b+c+/-d)	3,97,500	4.55	4.55

After the acquisition, holding of:			
a) Shares carrying voting rights	22,84,399	26.13	26.13
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	22,84,399	26.13	26.13
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Inter-se transfer		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	15.11.2021		
Equity share capital / total voting capital of the TC before the said acquisition / sale	87,43,750 equity shares of Rs. 10/- each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	87,43,750 equity shares of Rs. 10/- each		
Total diluted share/voting capital of the TC after the said acquisition	87,43,750 equity shares of Rs. 10/- each		

(* Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


Signature of the acquirer / seller / Authorised Signatory

Place: Hyderabad

Date: 15.11.2021
